Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
Nerea Zabaleta, Urja Bhatt, Cécile Hérate, Pauline Maisonnasse, Julio Sanmiguel, Cheikh Tacko Diop, Sofia Castore, Reynette Estelien, Dan Li, Nathalie Dereuddre‐Bosquet, Mariangela Cavarelli, Anne-Sophie Gallouët, Quentin Pascal, Thibaut Naninck, Nidhal Kahlaoui, Julien Lemaître, Francis Relouzat, Giuseppe Ronzitti, Hendrik Jan Thibaut, Emanuele Montomoli, James M. Wilson, Roger Le Grand, Luk H. Vandenberghe
Topics & Concepts
ImmunogenicityVirologyPandemicCoronavirus disease 2019 (COVID-19)ImmunologyImmunityPotencyMedicineVaccine efficacyViral vectorNeutralizing antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyAntigenImmune systemVaccinationVirusGeneDiseaseInfectious disease (medical specialty)Internal medicineRecombinant DNAIn vitroBiochemistrySARS-CoV-2 and COVID-19 ResearchVirus-based gene therapy researchImmunotherapy and Immune Responses